190 results on '"Macaulay R"'
Search Results
2. HTA267 Is the BBC Truly Impartial When Reporting on NICE’s Activities?
3. HTA35 G-BA Vs. InEK: Navigating Divergent Requirements Between the Two Key Bodies Behind Inpatient Drug Reimbursement in Germany
4. HTA5 An Evaluation of the NICE Early Value Assessment: What Is the Opportunity for Digital Therapeutics?
5. HPR162 Pharmaceutical Rebates – An Anglo-French Comparison
6. HTA56 The Post-Brexit UK Access Landscape: Does Project Orbis Significantly Accelerate Patient Access for Oncology Drugs in the UK Versus Europe?
7. HTA19 Is NICE Becoming Less ‘NICE’? a Time-Trend Analysis
8. HTA246 The SMC Ultra-Orphan Framework: 3-Year Report Card
9. HTA148 PRIME: Does Accelerated Marketing Authorization Translate Into Expedited Reimbursement and Patient Access?
10. HTA103 Revalmed – What Is the Potential Impact of This New Process on the Spanish Market Access System?
11. HTA33 Does the Selection of Participating Regions Impact the Outcome of Spanish Therapeutic Positioning Reports?
12. HPR86 Sustainability of Healthcare Systems in the Wake of COVID-19: The UK VPAS Case Study
13. HPR21 Project Orbis & the UK: 18-Month Report Card – Implications of UK Market Access for Oncology Drugs Prior to Europe
14. HTA57 UK Market Access: The Evolving Scope of NICE and NHSE Specialised Commissioning
15. HTA41 Consequences of Brexit: Medicines Access to Northern Ireland
16. HTA11 Access Barrier or Opportunity? Evolving Trends in NRDL Listings in China
17. POSB281 Do HTA Bodies Have an Issue with Diversity?
18. POSC272 How Does the Japanese CE-HTA Compare with ROW?
19. POSC271 NHS England: How Important Is This Emergent Stakeholder in UK Market Access?
20. P52 Surrogate Survival Endpoints: Are They Sufficient to Support Access?
21. P38 Sufficient Uptake of Highly Specialised Technologies?
22. SM4 The New SMC Ultra-Orphan Pathway: HTA Best Practice for Very Rare Diseases?
23. PRO40 Global Access Implications of GermanyÂ’s New GSAV LAW for Orphan Drugs
24. PNS73 The "NICEness" of NICE: A Time-Trend Analysis
25. PNS68 Latin America HTA: Brazil and Argentina Report Card
26. PNS78 Impact of COVID on Health Technology Assessment bodies
27. PNS64 Canadian Pricing and Reimbursement: Understanding the Biggest Hurdles in the Payer Landscape
28. PNS61 The Second Coming of the Nice Appeal Process?
29. PCN180 Is the Cancer Drugs Fund Functioning As Anticipated?
30. PCN174 Innovative Approaches to Cancer Therapy Provision in the COVID-Era
31. RW2 Synthetic Control Arms: Hype Versus Reality, the Payer Perspective
32. PNS9 Adverse Events Associated with External Reference Pricing in the USA
33. PMU64 HTA Best Practice for Inpatient Therapies: Comparing Sweden and Netherlands
34. PBI27 Multistakeholder Recommendations for LONG-TERM Sustainability of the Biosimilar Market in Europe: A Delphi Panel Consensus
35. PCN265 CHARACTERISATION OF MANAGED ACCESS AGREEMENTS UNDER THE NICE CANCER DRUGS FUND
36. PCN261 CAR-T THERAPIES: REIMBURSEMENTS ABOUND, BUT WITH STRINGS ATTACHED
37. PRO61 EVIDENCE OF VERY LOW UTILIZATION OF MEDICINES RECOMMENDED UNDER THE NICE HIGHLY SPECIALIZED TECHNOLOGY PATHWAY
38. PNS141 PATIENT INVOLVEMENT IN REIMBURSEMENT DECISION-MAKING - HOW ARE THEY INVOLVED? HOW SHOULD THEY BE INVOLVED?
39. PNS121 DOES THE CHOICE OF INDEPENDENT EXPERT COMMITTEE AFFECT ICER OUTCOMES?
40. PNS133 HTA BEST PRACTICE - NICE FAST TRACK APPROVALS: 2-YEAR REPORT CARD
41. PNS128 STILL EXCELLING? AN ASSESSMENT OF SOFTWARE USED IN NICE SINGLE TECHNOLOGY APPRAISALS AND ICER REPORTS IN 2019
42. PNS126 COMPARING EARLY ACCESS TO UNLICENSED MEDICINES IN UK, FRANCE, AND SWEDEN: CONSISTENT PRINCIPLES BUT INCONSISTENT OUTPUTS
43. PNS73 THE RIPPLE EFFECT – HOW PMPRB REFORMS COULD IMPACT DRUG PRICES GLOBALLY
44. PMU89 NEW AIFA INNOVATION ALGORITHM: 2 YEAR REPORT CARD
45. PMU80 THE ITALIAN INNOVATION ACCELERATION? BEST PRACTICE LESSONS OF REIMBURSEMENT INCENTIVES FOR INNOVATIVE PRODUCTS
46. PMU85 MISSION IMPOSSIBLE? REIMBURSEMENT SUCCESS WITH FAILED PHASE III TRIAL
47. HT1 EVIDENCE OF METHODOLOGICAL HETEROGENEITY IN THE NICE APPRAISAL PROCESS DEPENDING ON ERG: A REVIEW OF SURVIVAL EXTRAPOLATION APPROACHES IN ONCOLOGY
48. PRS48 UNLOCKING THE ACCESS CHALLENGES TO COPD
49. PRO111 REIMBURSEMENT OF ULTRA-ORPHAN MEDICINES: A NEW BEST-PRACTICE FRAMEWORK?
50. PRO112 THE HST TEST: GOOD, BETTER, BEST?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.